Guest Content

I. Executive Summary The pharmaceutical patent fortress is no longer just a legal concept. It is the primary financial architecture […]

Every January, without much fanfare, pharmaceutical companies raise their prices. In January 2024, nearly 2,000 drugs went up by an

How Section 3(d), compulsory licensing, and frugal innovation combine to make India the world’s most structurally disruptive pharmaceutical market, and

1. Why the NCE-Only Mental Model Is Costing You IP Value Key Takeaways The phrase ‘patent cliff’ has been overused

Why Effective Patent Life Is the Only Number That Matters Every pharmaceutical deal, licensing negotiation, and portfolio valuation ultimately hinges

Executive Overview: The High-Stakes Architecture of Market Exclusivity The global pharmaceutical industry operates at the precarious intersection of intellectual property

A deep-dive reference for pharmaceutical IP teams, R&D leads, payer strategy groups, and institutional investors. Executive Summary The question of

I. Why Patent Strategy Is Really Business Strategy Here is a number worth sitting with: the U.S. pharmaceutical industry spent

Executive Lead: Why Emerging Markets Are the Only Game That Matters The global generic drug market will reach approximately USD